A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context

Summary: Background: Sarcomas represent an extensive group of malignant diseases affecting mesodermal tissues. Among sarcomas, the clinical management of chondrosarcomas remains a complex challenge, as high-grade tumours do not respond to current therapies. Mutations in the isocitrate dehydrogenase...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Verónica Rey, Juan Tornín, Juan Jose Alba-Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña, Aurora Astudillo, Dominique Heymann, Karoly Szuhai, Judith V.M.G. Bovée, Agustín F. Fernández, Mario F. Fraga, Javier Alonso, René Rodríguez
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-04-01
Edice:	EBioMedicine
Témata:	Chondrosarcoma Enasidenib IDH2 Patient-derived models Personalized medicine
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2352396424001257
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!